Document is current

Article History

Accepted: 13 April 2025

First Online: 12 May 2025

Declarations

:

: This work was funded by CSL Vifor, which provided support for the model development and analysis and medical writing for this study.

: A.R.d.A. conceptualised and designed the study. E.S. was responsible for data analysis. All authors contributed to interpretation of the results, preparation and review of the manuscript, and approval of the final manuscript for publication.

: A.R.d.A. was an employee of CSL Vifor at the time of original drafts. E.S. and M.H. are employees of Health Economics and Outcomes Research Ltd. Health Economics and Outcomes Research Ltd. received fees from CSL Vifor in relation to this study. E.P. reports consultancy fees from CSL Vifor, AstratZeneca, Astellas and Novartis. M.S. reports consultancy fees from CSL Vifor, Novartis, Merck, Bayer, Abbott, Boehringer Ingelheim, AstraZeneca, Bioventrix, Servier, Novo Nordisk, Cardurion and AnaCardio.

: All data and material relevant to the analysis are presented in the publication or its supplementary material, with the exception of the model itself.

: Not applicable.

: Not applicable.

: Not applicable.

: The model used in this study was provided to the journal’s peer reviewers for their reference when reviewing the manuscript, but the model remains the intellectual property of CSL Vifor. The authors will respond to all enquiries regarding the details of the analysis upon reasonable request should these not have been answered by the information provided in the “Methods” section.